nab-paclitaxel + cisplatin

Phase 2Small molecule

HHuazhong University of Science and Technology

nab-paclitaxel + cisplatin is one of 80 small molecule programs targeting Esophageal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

341 competitors in Esophageal Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

48 2

Eloxatin

Teva

Phase 3

34 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

57 4

Paraplatin

AAvyxa

Phase 3

30 5

Adrucil

EElorac, Inc.

Phase 3

27 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

19 7

Erbitux

IImclone

Phase 3

16 8

Ellence

Merck & Co.

Phase 3

2 9

Yervoy

Bristol-Myers Squibb

Phase 3

2 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Esophageal Cancer

NCT06173986

Clinical

Trials by Indication[1]

Esophageal Cancer1 trial

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Recruiting·SShanghai Chest Hospital·Phase 1/2·NCT06173986·50 enrolled

Biliary Tract Cancer1 trial

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Unknown status·HHuazhong University of Science and Technology·Phase 2·NCT04692051·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for nab-paclitaxel + cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nab-paclitaxel + cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nab-paclitaxel + cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHuazhong University of Science and Technology

nab-paclitaxel + cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Esophageal Cancer1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News